A phase IB/II trial studying the combination of HLX208 with the anti-PD-1 antibody serplulimab (HLX10) in patients with BRAF V600E-mutant advanced solid tumors or NSCLC with PD-L1 TPS > 1% is also underway (NCT05641493). This evidence concerns the gene BRAF and non-small cell lung carcinoma.